finance.yahoo.com ·
royalty pharma q1 earnings call 092455040
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRoyalty Pharma is a royalty buyer in biopharma. Revenue miss vs estimate suggests slower-than-expected royalty inflows from underlying drugs, but EBITDA and EPS beat indicate cost discipline. No specific drug or pipeline event mentioned; impact is company-specific, not sector-wide. Commercial mechanism weak: earnings beat/miss with no supply/demand/regulatory trigger. Sector PHARMA_BIOTECH selected because company is a biopharma royalty aggregator, but no concrete commercial mechanism beyond earnings variance.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Royalty Pharma Q1 CY2026 revenue $630.6M vs estimate $874.1M (miss).
- Adjusted EPS $1.30 vs estimate $1.18 (beat).
- Adjusted EBITDA $889M vs forecast $816.7M (beat).
- Portfolio receipts grew 10% YoY; royalty receipts grew 13% YoY.
- Market cap $22.92B.